V940-011 A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)



Mary Beth Wilwerding, RN Admin@NEcancertrials.com



Available at Nebraska Hematology and Oncology, Lincoln, NE location

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*

Email*

Phone*

Message*